- Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for investigation of NP-120 (Ifenprodil) for the treatment of chronic cough
- Algernon filed an pre-IND meeting request in the event the company decides to move forward with a chronic cough Phase 2b study
- CEO Chris Moreau sat down with Dave Jackson to discuss the news
- Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) is up 4.47 per cent, trading at C$8.41 per share at 11:30 am EST
Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for its investigation of NP-120 (Ifenprodil) for the treatment of chronic cough.
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B).
CEO Chris Moreau sat down with Dave Jackson to discuss the news.
On September 20, 2021, Algernon reported positive trending interim data from the chronic cough part of its 20-patient proof-of-concept Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough study being conducted in Australia and New Zealand.
Algernon has filed a pre-IND meeting request to seek guidance from the FDA in the event the company decides to move forward with a chronic cough Phase 2b study in the U.S.
“We are very pleased with the response we received from the U.S. FDA. We look forward to the final data set from our IPF and chronic cough study so that we can plan our next steps.”
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) is up 4.47 per cent, trading at C$8.41 per share at 11:30 am EST.
